Members
Immunofyx
ImmunoFyx is a private early-stage biotechnology company focused on novel antibody fusion proteins targeting highly metastatic solid tumours. Up to 90% of cancer deaths are associated with metastases for which there are few treatment options. ImmunoFyx utilizes unique combinations of endogenous anti-cancer proteins to reduce tumour growth, angiogenesis and metastases.
member